TO THE EDITOR
Over recent years, the use of peripheral blood (PB) instead of bone marrow (BM) as a source for stem cells has been increasingly employed both in the autologous and in the allogeneic transplant setting. The advantages of peripheral blood stem cells (PBSC) include easier harvesting of stem cells, avoidance of anaesthesia and hospitalisation as well as improved yield of progenitor cells, and a more rapid and robust engraftment. However, it should also be taken into account that PBSC mobilisation requires the administration of haematopoietic cytokines (ie granulocyte colony-stimulating factor (G-CSF)) over several days, which stimulate proliferation and differentiation of myeloid cell lineage. 1 Extensive experience so far accumulated with G-CSF in patients being treated for neutropenia as well as in patients undergoing autologous stem cell mobilisation indicates that it is a safe procedure. Nevertheless, the parameters used for the safety evaluation have been rather crude and mainly focus on morphological and cytogenetic changes in haemopoietic cells. 2 Therefore, variations in other cell systems may have gone undetected. This is particularly relevant when considering the use of G-CSF in healthy volunteer individuals.
Analysis of gene expression profiles (GEP) using microarray technology has become a powerful tool for studying the expression of the most important genes in a single experiment. As such, the possibility to study thousands of genes and their cellular functions in the same experiment by microarrays could provide powerful information. 3 Despite the increasing use of PBSC transplantation, the changes induced by PBSC mobilisation and homing are not clear yet. To gain insight into the effects of G-CSF, used as PBSC mobilisation agent, the GEP of healthy donors was evaluated. In addition, in order to assess the duration of this effect, sequential studies on gene expression were also performed.
PB samples from nine healthy donors were studied. All donors were mobilised by using G-CSF (Filgastrim, Amgen) at a dose of 5 mg/kg/q12 h for 4 days, and peripheral stem cells were collected on day þ 5. For genomic profile purposes, the samples were collected just before G-CSF administration, and after mobilisation (day þ 5) in all nine donors investigated. In addition, samples were also collected 2 and 6 months after mobilisation in three of these donors. The study was approved by the local research ethics committee and written informed consent was obtained. Venous PB (20 ml) were obtained from each donor. Mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation. Data analysis were performed by Hierarchical clustering (Cluster and TreeView software), Multidimensional scaling method (BRB Array Tools version 3.0) and SAM algorithm ('Significant Analysis of Microarrays').
A two-dimensional hierarchical clustering analysis performed on 9203 genes passing the variation filter showed a dendogram with two major branches: one branch included all the donors after mobilisation with G-CSF, while in the other branch, the gene profiles from the donors before mobilisation and 2 and 6 months after G-CSF administration were grouped (Figure 1) . When multidimensional scaling analysis was performed, samples on day 0 and those on day þ 5 were also assigned into two well-differentiated groups.
Genes distinguishing the day 0 samples from the day þ 5 samples were identified as significant by the intersection of data sets from SAM analysis. A total of 761 genes distinguished the two groups: 374 increased their expression level, while 387 decreased their expression level after G-CSF (Table 1) . Our initial design included a revaluation of the donors 6 months after mobilisation with G-CSF. Moreover, in order to better determine the timing of normal recovery, an additional analysis just 2 months after G-CSF administration was also performed. No gene was found to be under-or overexpressed after comparing the samples before G-CSF and 2 or 6 months after G-CSF. Moreover, Figure 1 Dendogram from a hierarchical cluster analysis of the 24 PB samples from healthy donors. Based on the expression of 9203 genes passing a variation filter generated by using Cluster and TreeView programs. Horizontal bars along the dendogram represent samples 5 days after G-CSF (a) and samples before G-CSF as well as 2 and 6 months after G-CSF (b). Table 1 Genes differentially expressed between mononuclear cells obtained before and after donor mobilisation with G-CSF (day +5) Correspondence no differences between the gene expression of the donors evaluated at 2 months and those studied at 6 months after G-CSF administration were observed. The results of the present study revealed that, although important changes in the expression of hundreds of genes are observed in the first days after mobilisation, these effects are temporal and returned to normal values within the first 2 months after G-CSF.
Deregulation in the function of several genes has been already described after G-CSF. Thus, direct in vivo studies have shown an overexpression of CD11b and an activation of neutrophils leading to the release of the contents of either specific (MMP-8, MMP-9) or azurophilic (elastase, cathepsin G, proteinase 3) granules. 4 An upregulation of all the genes coding these molecules was observed in our study on the day þ 5 after G-CSF. As expected, ICAM2, a gene involved Gene symbol Name Representative public ID Score in cell adhesion, was downregulated following G-CSF in order to facilitate cell migration. In addition, the present study showed a deregulation of other genes involved in cell adhesion. Interestingly, some small GTPases and Cdc42 were overexpressed. All of these genes are upregulated in murine models, and lead to an increase in cell migration of stem cells. 5 Other overexpressed GTPases, such as RAB family, are considered master regulators of cellular membrane transport, and, in collaboration with tethering factors and 'SNARE' complexes, regulate the vesicle formation and fusion with the target membrane. 6 It should be noted that a large number of genes involved in protein biosynthesis and protein folding were downregulated. Most of them encode for ribosomal proteins, while others, such as initiation factor IF2, are essential for the initiation of protein synthesis. 7 This repression of both transcription and translation programs could be interpreted as defensive mechanisms to maintain normal homeostasis. Thus, in the genomic profile on the 5th day after mobilisation, the protein biosynthesis was decreased. This result could explain why there was a halt in the mobilisation of progenitor cells after the leucocyte peak observed on days 4-5 after G-CSF. 1, 4 Most of the genes involved in the immune response were downregulated. The present study shows a decreased expression of T-cell-related genes, including genes coding for TCR a, d, and g, as well as several genes for HLA complex. In addition, the expression of GATA3, a master key in T-cell development, was also downregulated. These results could contribute to a better understanding of the transient defect in the T-cell-mediated immune response previously reported. 8 One of the side effects in patients receiving G-CSF is a mild thrombocytopenia. The GEP of genes involved in the haematopoiesis showed that some genes related to megakaryotcyitc proliferation (PF4 and PTFN4) were underexpressed. In contrast, genes involved in the erythropoiesis, such as TIMP1 and ETS-2, were upregulated. These results could help to explain not only the thrombocytopenia induced by G-CSF but also the synergistic effect observed in patients treated with G-CSF plus EPO on red cell count. As far as genes involved in blood coagulation is concerned, only two genes (FV and Annexin A5) were found to be overexpressed. The latter protein shows an anticoagulant effect. According to these results, the prothrombotic status suggested after G-CSF administration would not be supported by our gene analysis. Nevertheless, we have found an important overexpression of genes associated with neutrophil activation (elastase, CD11b), which may favour a transient mild hypercoagulable status after G-CSF. 4 Regarding proliferation and cell cycle, several genes were deregulated. Interestingly BTG1, ATM and MYC were downregulated. These inhibitions could induce cell cycle arrest, promote maturation block in addition to differentiation, as well as an increased sensitivity to apoptosis. The deregulation of these genes involved in cell cycle could explain the increased levels of mature leucocytes showed after G-CSF.
It should be noted that the expression of all the deregulated genes at day þ 5 returned to normal profile within the first 2 months after G-CSF mobilisation and the situation remained normal 6 months later. These results are in accordance with clinical studies showing no significant side effects in healthy donors mobilised with G-CSF. As such, this therapy would appear to be safe for healthy volunteer donors of haematopoietic stem cells.
